128 related articles for article (PubMed ID: 8235308)
41. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
42. Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin.
Szwed M; Kania KD; Jozwiak Z
Cell Oncol (Dordr); 2014 Dec; 37(6):421-8. PubMed ID: 25410120
[TBL] [Abstract][Full Text] [Related]
43. The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
Killion JJ; Beltran P; O'Brian CA; Yoon SS; Fan D; Wilson MR; Fidler IJ
Oncol Res; 1995; 7(9):453-9. PubMed ID: 8835289
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic analysis of protein-conjugated doxorubicin (DXR) and its degraded adducts in DXR-sensitive and -resistant rat hepatoma cells.
Takahashi N; Asakura T; Ohkawa K
Anticancer Drugs; 1996 Aug; 7(6):687-96. PubMed ID: 8913438
[TBL] [Abstract][Full Text] [Related]
45. Distribution characteristics of carboxymethylpullulan-peptide-doxorubicin conjugates in tumor-bearing rats: different sequence of peptide spacers and doxorubicin contents.
Nogusa H; Yamamoto K; Yano T; Kajiki M; Hamana H; Okuno S
Biol Pharm Bull; 2000 May; 23(5):621-6. PubMed ID: 10823676
[TBL] [Abstract][Full Text] [Related]
46. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
47. Improved in vivo antitumor efficacy and reduced systemic toxicity of carboxymethylpullulan-peptide-doxorubicin conjugates.
Nogusa H; Hamana H; Uchida N; Maekawa R; Yoshioka T
Jpn J Cancer Res; 2000 Dec; 91(12):1333-8. PubMed ID: 11123434
[TBL] [Abstract][Full Text] [Related]
48. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity.
Gijsens A; Missiaen L; Merlevede W; de Witte P
Cancer Res; 2000 Apr; 60(8):2197-202. PubMed ID: 10786684
[TBL] [Abstract][Full Text] [Related]
49. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle.
Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ
Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184
[TBL] [Abstract][Full Text] [Related]
50. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation.
Zhu B; Zhang H; Yu L
Biomed Pharmacother; 2017 Feb; 86():547-554. PubMed ID: 28024291
[TBL] [Abstract][Full Text] [Related]
51. Protein binding of 4-hydroxybenzoic acid and 4-hydroxy-3-methoxybenzoic acid to human serum albumin and their anti-proliferation on doxorubicin-sensitive and doxorubicin-resistant leukemia cells.
Myint O; Wattanapongpitak S; Supawat B; Kothan S; Udomtanakunchai C; Tima S; Tungjai M
Toxicol Rep; 2021; 8():1381-1388. PubMed ID: 34285884
[TBL] [Abstract][Full Text] [Related]
52. [Targeting of chlorine E6 by EGF increasing its photodynamic activity in selective ways].
Gijsens A; De Witte P
Verh K Acad Geneeskd Belg; 2000; 62(4):329-52. PubMed ID: 11004908
[TBL] [Abstract][Full Text] [Related]
53. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement.
Naito M; Tsuruo T
Cancer Res; 1989 Mar; 49(6):1452-5. PubMed ID: 2924298
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of doxorubicin-transferrin conjugate in apoptosis induction in human leukemia cells through reactive oxygen species generation.
Szwed M; Laroche-Clary A; Robert J; Jozwiak Z
Cell Oncol (Dordr); 2016 Apr; 39(2):107-18. PubMed ID: 26611752
[TBL] [Abstract][Full Text] [Related]
55. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice.
Yang HM; Reisfeld RA
Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1189-93. PubMed ID: 3422487
[TBL] [Abstract][Full Text] [Related]
56. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
[TBL] [Abstract][Full Text] [Related]
57. TRIB2 knockdown as a regulator of chemotherapy resistance and proliferation via the ERK/STAT3 signaling pathway in human chronic myelogenous leukemia K562/ADM cells.
Ma X; Zhou X; Qu H; Ma Y; Yue Z; Shang W; Wang P; Xie S; Li Y; Sun Y
Oncol Rep; 2018 Apr; 39(4):1910-1918. PubMed ID: 29436678
[TBL] [Abstract][Full Text] [Related]
58. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
59. Characterization of the anti-cancer activity of transferrin-adriamycin conjugates.
Sizensky JA; Barabas K; Faulk WP
Am J Reprod Immunol; 1992; 27(3-4):163-6. PubMed ID: 1418408
[TBL] [Abstract][Full Text] [Related]
60. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor.
Prakash J; Beljaars L; Harapanahalli AK; Zeinstra-Smith M; de Jager-Krikken A; Hessing M; Steen H; Poelstra K
Int J Cancer; 2010 Apr; 126(8):1966-1981. PubMed ID: 19795464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
